WebDoctor Encyclopedia

Soft-tissue sarcomas

Angiosarcoma

Angiosarcoma is a rare, aggressive cancer of the cells lining blood and lymph vessels, most often affecting the scalp and face of older people or the breast after radiotherapy.

Medically reviewed Last reviewed October 27, 2026

What is angiosarcoma?

Angiosarcoma is a rare, fast-growing cancer that starts in the cells lining the inside of blood vessels or lymph vessels (endothelial cells). Because blood vessels run through every part of the body, angiosarcoma can develop almost anywhere.

It is most often found in the skin of the scalp and face in older people, in the breast (often after radiotherapy for breast cancer), and in the liver, spleen and heart. It belongs to the large family of soft tissue sarcomas, but it behaves differently from most of them.

Angiosarcoma tends to spread along the skin further than can be seen, to come back after treatment and to spread to the lungs and other organs. Treatment usually combines surgery, radiotherapy and drug treatment, and is best planned at a specialist sarcoma centre.

1. How common is it?

Angiosarcoma accounts for about 1-2% of all soft tissue sarcomas. According to the US National Cancer Institute, about 1 person per million is diagnosed with it each year.

Feature Details
Typical age Most common over 70; breast angiosarcoma without prior radiotherapy affects younger women
Sex Scalp and face angiosarcoma is about twice as common in men; breast forms affect women
Most common site Skin of the head and neck, about half of all cases
Other sites Breast, chest wall, limbs with chronic swelling, liver, spleen, heart, bone and deep soft tissue

2. Types and causes

Most angiosarcomas have no known cause. In some people, a clear risk factor can be identified.

Type Who it affects Key features
Scalp and face (cutaneous) Older adults, more often men Linked with long-term sun exposure; often spreads widely in the skin
Radiation-associated Mainly women treated with radiotherapy for breast cancer Appears in the treated area, usually 5-10 years after radiotherapy
Lymphoedema-associated (Stewart-Treves syndrome) People with long-standing swelling of a limb Classically in the arm after breast surgery with lymph node removal, often 10 years later
Primary breast Younger women, often 30-50 Starts deep in breast tissue without previous radiotherapy
Liver Adults Linked with vinyl chloride, arsenic and the old X-ray contrast agent Thorotrast
Heart and other organs Adults, often younger The most common primary sarcoma of the heart, usually in the right atrium

The risk of angiosarcoma after breast radiotherapy is very small. Radiotherapy prevents far more cancers than it causes, and its benefits clearly outweigh this rare risk.

Genetic changes

Most angiosarcomas that follow radiotherapy or chronic lymphoedema have extra copies of the MYC gene. Testing for MYC helps pathologists tell these tumours apart from harmless vascular changes after radiotherapy.

Scalp and face angiosarcomas often carry many genetic changes caused by ultraviolet light. This high mutation burden may explain why some respond well to immunotherapy. Rare inherited changes in the POT1 gene have been linked with angiosarcoma of the heart.

3. How does it look?

The appearance of angiosarcoma depends on where it grows. Skin angiosarcoma often looks harmless at first, which can delay diagnosis.

3.1 Skin of the scalp and face

  • Early disease often looks like a bruise that does not fade. It may be a purple, red or blue patch on the scalp, forehead or around the eyes.
  • Over time, the patch may become raised, form lumps (nodules) or turn into an open sore (ulcer).
  • The tumour bleeds easily, for example when combing hair or shaving.
  • The area may be swollen, and swelling around the eyes or face can be the main sign.
  • There are often several patches, and the cancer usually extends well beyond the visible edge.

It is easily mistaken for a bruise, rosacea, eczema, an infection of the skin (cellulitis) or a benign blood vessel growth.

3.2 Breast and chest wall

Radiation-associated angiosarcoma appears in the skin of the treated breast or chest wall as one or more bruise-like patches, purple lumps or areas of thickened, discoloured skin. It can be confused with the normal skin changes that follow radiotherapy.

Primary breast angiosarcoma usually presents as a painless lump deep in the breast. Sometimes the skin over it has a bluish or purple tint.

3.3 Limbs with lymphoedema

In Stewart-Treves syndrome, red-purple patches and lumps appear on a chronically swollen arm or leg. They may spread quickly and bleed.

3.4 Internal organs

Angiosarcoma of the liver, spleen or heart cannot be seen from the outside. On CT or MRI it appears as a mass, or several masses, with areas of bleeding.

3.5 Under the microscope

The pathologist sees irregular, interconnecting blood channels lined by abnormal endothelial cells. Higher-grade areas show solid sheets of cells. Some tumours are made of large, round cells (epithelioid angiosarcoma) and can look like a carcinoma or melanoma.

Special stains such as CD31, ERG and CD34 confirm that the cells come from blood vessels. A MYC test supports a diagnosis of radiation-associated angiosarcoma.

4. Symptoms

Symptoms depend on where the tumour is.

4.1 Skin angiosarcoma

Symptom Typical description
Bruise-like patch Purple or dark red, does not fade over weeks and slowly enlarges
Lumps Raised, soft or firm, purple or red nodules
Bleeding From minor knocks or scratching; may be hard to stop
Swelling Of the face, eyelids or scalp
Ulcers Open sores that do not heal, sometimes with crusting
Pain or tenderness Usually later, as the tumour grows

4.2 Breast and chest wall

  • A new patch of bruise-like or purple skin in a previously treated breast or chest wall
  • Thickening or swelling of the skin
  • A painless, growing lump deep in the breast

4.3 Internal organs

  • Liver: pain in the upper abdomen, a swollen abdomen, jaundice, weight loss, or sudden bleeding into the abdomen
  • Spleen: pain in the left upper abdomen, anaemia, or sudden collapse if the spleen ruptures
  • Heart: breathlessness, chest pain, swelling of the legs, or fluid around the heart
  • Deep soft tissue: an enlarging lump, sometimes with bleeding into it

4.4 Symptoms of spread

Angiosarcoma most often spreads to the lungs, where it can cause cough, coughing up blood, breathlessness or a collapsed lung (pneumothorax). It can also spread to the liver, bones, lymph nodes and other parts of the skin.

When to see a doctor

See a doctor if you have a bruise that has not faded within a few weeks without a clear reason, especially on the scalp or face. The same applies to a new purple patch or lump in a breast treated with radiotherapy, or in a limb with long-standing swelling. Bleeding from a skin lesion after only a minor knock also needs checking.

5. Diagnosis

5.1 Biopsy

A biopsy is essential. For skin lesions, a punch or incisional biopsy is usually taken. Deeper tumours are sampled with a core needle guided by ultrasound or CT. The tissue should be reviewed by a pathologist with experience in sarcoma.

5.2 Imaging

Test Purpose
MRI Shows how far the tumour extends in the scalp, breast or limb, and helps plan surgery and radiotherapy
CT of the chest, abdomen and pelvis Checks for spread, especially to the lungs and liver
PET-CT Used in some cases to look for spread
Echocardiogram or cardiac MRI For tumours of the heart

5.3 Staging

There is no staging system designed only for angiosarcoma. Doctors use the AJCC soft tissue sarcoma system for the relevant body site. This system takes into account tumour size, spread to lymph nodes and distant organs, and grade.

Angiosarcoma is usually treated as a high-grade sarcoma. In practice, the main question is whether the disease is localised and can be treated with surgery and radiotherapy, or has spread.

6. Treatment

Treatment should be planned by a multidisciplinary sarcoma team. It depends on the site and extent of the tumour and on the person’s general health.

6.1 Localised disease

Treatment Role Key points
Surgery Main curative treatment Aims to remove the tumour with wide clear margins; can be difficult on the scalp and face
Radiotherapy Usually given after surgery, or before it Covers a wide area around the tumour because of hidden spread; reduces local recurrence
Chemotherapy Sometimes before or after surgery Taxanes or doxorubicin; may shrink the tumour first; benefit after surgery not proven

Scalp and face angiosarcoma often involves a larger area than can be seen. Surgery may need skin grafts or flaps to close the wound.

When the disease is too widespread for surgery, radiotherapy combined with weekly paclitaxel is commonly used. Some centres also give chemotherapy before surgery to shrink the tumour.

Radiation-associated angiosarcoma of the breast is usually treated by removing all of the previously irradiated skin, often with a mastectomy. The wound is then reconstructed. Further radiotherapy is sometimes possible, using special techniques such as hyperfractionation.

Liver, spleen and heart tumours are removed surgically when possible. For heart angiosarcoma, surgery is often combined with chemotherapy.

6.2 Advanced or metastatic disease

Treatment How it is given Key facts
Weekly paclitaxel Intravenous infusion, usually 3 weeks out of 4 Often the first choice, particularly for scalp and face angiosarcoma
Doxorubicin Intravenous infusion every 3 weeks Standard sarcoma drug; can damage the heart at high total doses
Docetaxel Intravenous infusion An alternative taxane
Pazopanib Daily tablet Blocks blood vessel growth signals; used after chemotherapy
Immunotherapy Intravenous infusion Ipilimumab plus nivolumab or pembrolizumab; best results in scalp and face tumours; used in trials or off-label

In the ANGIOTAX trial of weekly paclitaxel, tumours shrank in about one in five patients. The disease was controlled for a median of about four months. Adding bevacizumab to paclitaxel did not improve results in a randomised trial.

In a US trial of ipilimumab plus nivolumab, about a quarter of all patients responded. Among people with angiosarcoma of the scalp or face, the response rate was about 60%, and some responses were long-lasting.

6.3 Supportive care

Bleeding and ulcerated tumours can be managed with special dressings and short courses of radiotherapy. Good pain control, nutrition and psychological support are an important part of care, especially in advanced disease.

7. Prognosis

Angiosarcoma is an aggressive cancer, and the outlook is generally poorer than for many other soft tissue sarcomas.

  • Overall, about 30-40% of people are alive five years after diagnosis.
  • The outlook is better for small tumours that can be removed completely with clear margins, followed by radiotherapy.
  • Large tumours, involvement of internal organs and spread at diagnosis carry a worse outlook.
  • For metastatic disease, median survival has historically been under a year. Newer drug treatments and immunotherapy are improving this for some people.
  • Local recurrence is common, especially in scalp and face tumours. Spread to the lungs is the most common type of distant relapse.

8. Follow-up and living with angiosarcoma

8.1 Follow-up

Because recurrence is common and usually happens within the first few years, follow-up is close.

  • Examination of the skin and scar every 3 months for the first two to three years, then less often
  • CT scans of the chest, and of other areas when needed, every 3-6 months at first
  • MRI of the original site if a recurrence is suspected

8.2 Everyday life

  • Check the treated area regularly and report any new bruise-like patch, lump or bleeding without delay.
  • Protect the scalp and face from the sun with a hat and sunscreen, especially after radiotherapy.
  • People with lymphoedema should keep up compression and skin care, and report any new skin changes on the swollen limb.
  • Wound care after surgery or radiotherapy of the scalp can take time; specialist nurses can help.
  • Sarcoma charities and patient groups provide information and support for people with this rare cancer.

Resources

  1. Young, R.J. et al. (2010) ‘Angiosarcoma’, The Lancet Oncology, 11(10), pp. 983-991.
  2. Florou, V. and Wilky, B.A. (2018) ‘Current and future directions for angiosarcoma therapy’, Current Treatment Options in Oncology, 19(3), p. 14.
  3. Manner, J. et al. (2010) ‘MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema’, American Journal of Pathology, 176(1), pp. 34-39.
  4. Painter, C.A. et al. (2020) ‘The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research’, Nature Medicine, 26(2), pp. 181-187.
  5. Penel, N. et al. (2008) ‘Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study’, Journal of Clinical Oncology, 26(32), pp. 5269-5274.
  6. Ray-Coquard, I.L. et al. (2015) ‘Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: a randomized phase II trial’, Journal of Clinical Oncology, 33(25), pp. 2797-2802.
  7. Wagner, M.J. et al. (2021) ‘Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)’, Journal for ImmunoTherapy of Cancer, 9(8), e002990.
  8. Gronchi, A. et al. (2021) ‘Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(11), pp. 1348-1365.
  9. National Cancer Institute (2026) Angiosarcoma. Available at: https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/rare-vascular-tumors/angiosarcoma (Accessed: October 2026).
  10. National Cancer Institute (2026) Adult Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.